Abstract:Background Lipocalin‐2 (LCN‐2) is an osteokine that suppresses appetite, stimulates insulin secretion, regulates bone remodeling, and is induced by proinflammatory cytokines. The aim of this work was to investigate the participation of LCN‐2 in periodontitis associated with type 2 diabetes (T2D) by evaluating alveolar bone loss, glycemic control, inflammation, and femur fragility. Methods A murine model of periodontitis with T2D and elevated LCN‐2 concentration was used. Functional LCN‐2 inhibition was achieved using an anti‐LCN‐2 polyclonal antibody, and isotype immunoglobulin G was used as a control. The alveolar bone and femur were evaluated by micro‐CT. Glucose metabolism was determined. Tumor necrosis factor (TNF‐α) and receptor activator of nuclear factor kappa‐B ligand (RANKL) levels in alveolar bone lysates were quantified using ELISA, and serum cytokines were quantified using flow cytometry. A three‐point bending test was performed in the femur, and RANKL levels were measured in femur lysates using ELISA. Results Functional inhibition of LCN‐2 in T2D–periodontitis mice decreased alveolar bone loss in buccal and palatal surfaces and preserved the microarchitecture of the remaining bone, decreased TNF‐α and RANKL in alveolar bone, reduced hyperglycemia, glucose intolerance, and insulin resistance, and increased insulin production through improving the functionality of pancreatic β cells. Furthermore, this inhibition increased serum free‐glycerol levels, decreased serum interleukin (IL)‐6, increased serum IL‐4, and reduced femur fragility and RANKL expression in the femur. Conclusions LCN‐2 participates in periodontitis associated with T2D. Inhibiting its function in mice with T2D and periodontitis improves pancreatic β‐cell function, and glucose metabolism and decreases inflammatory cytokines and bone‐RANKL levels, which results in the preservation of femoral and alveolar bone microarchitecture. Plain Language Summary In this study, we explored the role of a bone protein known as lipocalin‐2 (LCN‐2) in the connection between periodontitis and type 2 diabetes (T2D). Periodontitis is a destructive gum and alveolar bone disease. LCN‐2 levels are increased in both T2D and periodontitis. Using a mouse model of T2D with periodontitis, we examined how blocking LCN‐2 function affected various aspects of these two diseases. We found that this inhibition led to significant improvements. First, it reduced alveolar bone loss and preserved bone structure by decreasing local inflammation and bone resorption. Second, it improved glucose and lipid metabolism, leading to better blood‐sugar control and decreased insulin resistance. Blocking the functions of LCN‐2 also decreased systemic inflammation throughout the body and strengthened bone integrity. Overall, our results suggest that LCN‐2 plays a crucial role in the periodontitis associated with T2D. By inhibiting LCN‐2 function, we were able to improve pancreatic function, improve glucose metabolism, reduce inflammation, and enhance bone health. Targeting LCN‐2 could be a promising strategy for the harmful effects of T2D and periodontitis.

Sclerostin antibody corrects periodontal disease in type 2 diabetic mice

Periodontitis Contributes to Aberrant Metabolism in Type 2 Diabetes Mellitus Rats by Stimulating the Expression of Adipokines

Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2 diabetes: a randomized study.

[Effects of Non-Surgical Periodontal Treatment on Clinical Response, Serum Inflammatory Parameters, and Metabolic Control of Type 2 Diabetes Patients with Moderate to Severe Periodontitis].

Type 1 diabetes mellitus leads to gingivitis and an early compensatory increase in bone remodeling

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)

Sclerostin Antibody Treatment Causes Greater Alveolar Crest Height and Bone Mass in an Ovariectomized Rat Model of Localized Periodontitis.

An Adiponectin Receptor Agonist Reduces Type 2 Diabetic Periodontitis.

Sclerostin Inhibition Reverses Systemic, Periarticular and Local Bone Loss in Arthritis

Human periodontitis-associated salivary microbiome affects the immune response of diabetic mice

Ectopic Colonization and Immune Landscapes of Periodontitis Microbiota in Germ-Free Mice With Streptozotocin-Induced Type 1 Diabetes Mellitus.

Lipocalin‐2 as a fundamental protein in type 2 diabetes and periodontitis in mice

Remodeling of the periodontal ligament and alveolar bone during axial tooth movement in mice with type 1 diabetes

Dysregulation of CXCL1 Expression and Neutrophil Recruitment in Insulin Resistance and Diabetes-Related Periodontitis in Male Mice

Hyperglycemia and xerostomia are key determinants of tooth decay in type 1 diabetic mice

Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells

Inhibition of GDF11 could promote bone healing in the tooth extraction socket and facilitate mesenchymal stem cell osteogenic differentiation in T2DM pigs

Calcitriol-enhanced autophagy in gingival epithelium attenuates periodontal inflammation in rats with type 2 diabetes mellitus

Complement 3 Mediates Periodontal Destruction In Patients With Type 2 Diabetes By Regulating Macrophage Polarization In Periodontal Tissues

Periodontitis Induced by Porphyromonas Gingivalis Drives Impaired Glucose Metabolism in Mice

Oral Plaque from Type 2 Diabetic Patients Reduces the Clonogenic Capacity of Dental Pulp-Derived Mesenchymal Stem Cells